Zami Aberman
2008
In 2008, Zami Aberman earned a total compensation of $765.9K as Chief Executive Officer at Pluristem Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $41,287 |
|---|---|
| Salary | $312,565 |
| Stock Awards | $412,051 |
| Total | $765,903 |
Aberman received $412.1K in stock awards, accounting for 54% of the total pay in 2008.
Aberman also received $41.3K in non-equity incentive plan and $312.6K in salary.
Rankings
In 2008, Zami Aberman's compensation ranked 5,198th out of 9,135 executives tracked by ExecPay. In other words, Aberman earned more than 43.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,198 out of 9,135 | 43rd |
Division Manufacturing | 1,889 out of 3,436 | 45th |
Major group Chemicals And Allied Products | 377 out of 815 | 54th |
Industry group Drugs | 234 out of 597 | 61st |
Industry Biological Products, Except Diagnostic Substances | 39 out of 118 | 67th |
Source: SEC filing on November 23, 2009.
Aberman's colleagues
We found one more compensation record of an executive who worked with Zami Aberman at Pluristem Therapeutics in 2008.
2008
Yaky Yanay
Pluristem Therapeutics
Chief Financial Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020
Pluristem Therapeutics CEO Zami Aberman's 2018 pay falls 83% to $593K
April 25, 2019